aripiprazole (Mezofy)

Quick answers

What is aripiprazole (Mezofy)?

Mezofy is an oral dissolving film formulation of aripiprazole approved for schizophrenia in adults and adolescents aged 13 and older. It dissolves on the tongue without water, which can help when medication refusal or swallowing difficulty is a concern.

What is Mezofy?

Mezofy is a brand name for aripiprazole (Mezofy).

What is Mezofy (aripiprazole (Mezofy)) used for?

Label indications include: Schizophrenia in adults and adolescents aged 13 years and older.

What drug class is Mezofy (aripiprazole (Mezofy))?

Atypical Antipsychotic.

What is the mechanism of action of Mezofy (aripiprazole (Mezofy))?

Oral dissolving film formulation of aripiprazole (D2/D3 partial agonist with 5-HT1A partial agonism and 5-HT2A antagonism) designed to improve medication adherence by dissolving in the mouth without water.

What strengths does Mezofy (aripiprazole (Mezofy)) come in?

Oral dissolving film placed on the tongue; dissolves without water. Bioequivalent to aripiprazole tablets (label).

Is Mezofy (aripiprazole (Mezofy)) a controlled substance?

No — it is not scheduled as a controlled substance under U.S. federal law.

General information

Mezofy fills an adherence-focused niche: inpatient and residential settings where observed dosing is needed, patients with dysphagia, and situations where tablet refusal limits treatment. U.S. availability is expected in the first half of 2026.

Mechanism of action

Refer to the Glossary entry on Neurotransmitters for background on receptor systems involved in serious mental illness.

• D2/D3 partial agonism (primary antipsychotic mechanism).
• 5-HT1A partial agonism (anxiolytic contribution).
• 5-HT2A antagonism.

Metabolism & pharmacokinetics

• Aripiprazole is metabolized primarily via CYP2D6 and CYP3A4. The active metabolite dehydro-aripiprazole provides ~40% of exposure and has a ~94-hour half-life (label).
• Oral film bioequivalence to tablets means no dose adjustment when switching formulations (label).
• Strong CYP2D6 or CYP3A4 inhibitors increase exposure and may require dose reduction; strong CYP3A4 inducers can markedly lower levels (label).

Dosing & administration

• The oral film is placed on the tongue and dissolves without water. Handle with dry hands and place on the tongue immediately after opening the pouch. Designed for observed administration and patients who have difficulty swallowing tablets.
• Schizophrenia (adults): recommended dose is 10 to 15 mg once daily, with a maximum of 30 mg/day. No titration is strictly required, though clinical judgment guides starting dose (label).
• Schizophrenia (adolescents aged 13+): target dose is 10 mg/day; dose adjustments follow the same principles as tablet aripiprazole (label).

Monitoring & labs

• Weight/BMI and waist circumference; fasting lipids and glucose/HbA1c at baseline and periodically.
• Movement disorder monitoring (akathisia, parkinsonism, tardive dyskinesia), especially after initiation and dose adjustments.
• Monitor for compulsive behaviors (gambling, eating, shopping) and counsel patients and caregivers.
• Orthostatic vital signs during dose initiation.

Adverse effects

Interactions

• Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine) or strong CYP3A4 inhibitors (e.g., ketoconazole) increase aripiprazole exposure; dose reduction may be needed (label).
• Strong CYP3A4 inducers (e.g., carbamazepine) can markedly lower aripiprazole levels; dose increases may be necessary during co-administration (label).
• Additive sedation can occur with other CNS depressants; clinical monitoring is individualized.

Other useful information

• The oral film addresses a practical gap in aripiprazole formulations: patients who refuse tablets, have swallowing difficulty, or require observed dosing may benefit from a formulation that dissolves on the tongue without water.
• For patients stable on aripiprazole tablets, switching to Mezofy is straightforward with no dose adjustment needed (label).

References